



Fidson Healthcare Plc
... We value life

FIDSON HEALTHCARE PLC
Lagos, Nigeria
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2023

[Table of Contents](#)

Statement of Profit or Loss and Other Comprehensive Income	1
Statement of financial position	2
Statement of Changes in Equity	3
Statement of Cash Flows	4
Notes to the financial statements.	5

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

Statement of Profit or Loss and Other Comprehensive Income

	Notes	2023		2022	
		July-Sep ₦'000	Jan-Sep ₦'000	July-Sep ₦'000	Jan-Sep ₦'000
Revenue	5	14,793,989	40,373,977	11,048,672	31,428,149
Cost of sales	6	<u>(10,290,718)</u>	<u>(24,813,124)</u>	<u>(6,422,339)</u>	<u>(16,938,149)</u>
Gross profit		4,503,271	15,560,853	4,626,333	14,490,000
Other operating income	7	141,121	338,802	272,561	684,824
Administrative expenses	8	(1,553,109)	(5,607,211)	(2,739,465)	(5,264,618)
Selling and distribution expenses	9	<u>(1,332,099)</u>	<u>(3,642,342)</u>	<u>(600,813)</u>	<u>(3,562,461)</u>
Operating profit		1,759,185	6,650,102	1,558,615	6,347,745
Finance costs	10	(582,229)	(1,379,729)	(488,862)	(1,285,998)
Finance income	11	<u>7,066</u>	<u>19,947</u>	<u>21,066</u>	<u>34,331</u>
Profit before tax	12	1,184,021	5,290,320	1,090,999	5,096,078
Income tax provision	13a	<u>(384,807)</u>	<u>(1,719,354)</u>	<u>(354,575)</u>	<u>(1,656,225)</u>
Profit for the Period		<u>799,214</u>	<u>3,570,966</u>	<u>736,424</u>	<u>3,439,853</u>
Earnings per share – basic (in kobo)					
Basic and diluted		<u>35</u>	<u>156</u>	<u>32</u>	<u>150</u>

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

Statement of financial position
As at 30 September 2023

ASSETS	Notes	Sep-23 N'000	Dec-22 N'000
Non-current assets			
Property, plant and equipment	14	19,437,807	19,565,588
Right of use assets	15	327,621	380,817
Investment property	16	-	-
Intangible assets	17	44,763	23,544
Available- for-sale investments	18a	6,290	4,800
Loans and receivables	18b	15,813	14,692
Other non-current financial asset	19/19a	181,761	174,542
		<u>20,014,056</u>	<u>20,163,983</u>
Current assets			
Inventories	20	13,459,348	14,606,786
Trade and other receivables	21	9,312,814	4,249,396
Prepayments	22	4,237,497	1,845,990
Cash and cash equivalents	23	3,856,327	2,115,136
		<u>30,865,985</u>	<u>22,817,308</u>
Total assets		<u>50,880,042</u>	<u>42,981,291</u>
Equity and liabilities			
Equity			
Issued share capital	32	1,147,498	1,147,498
Share premium	33	4,829,614	4,829,614
Retained earnings		13,250,530	10,941,812
Financial Asset reserve	34	1,845	355
		<u>19,229,487</u>	<u>16,919,279</u>
Non-current liabilities			
Interest bearing loans and borrowings	24	7,748,029	5,746,439
Obligation under Finance Lease	25	-	-
Retirement benefit obligation	26	262,325	263,602
Government grant	27	1,099,427	651,291
Deferred tax liability	13c	1,389,945	1,389,945
		<u>10,499,726</u>	<u>8,051,277</u>
Current liabilities			
Trade and other payables	29	9,637,346	7,015,730
Interest bearing loans and borrowings	24	3,836,873	5,798,413
Bank Overdraft	23	742,705	290,004
Other financial liabilities	30	5,000,000	3,000,000
Obligations under Finance Lease	25	-	55,581
Government grant	27	106,411	346,595
Deferred revenue	28	-	-
Income tax payable	13b	1,719,354	1,396,272
Unclaimed dividend	31b	108,140	108,140
		<u>21,150,828</u>	<u>18,010,735</u>
Total liabilities		<u>31,650,554</u>	<u>26,062,012</u>
Total equity and liabilities		<u>50,880,041</u>	<u>42,981,291</u>

SIGNED ON BEHALF OF THE BOARD OF DIRECTORS ON 26 October 2023



Fidelis Ayebae
Managing Director/CEO
FRC/2014/CIANG/0000002376



Abiola Adebayo
Deputy Managing Director
FRC/2013/PSNIG/0000002376



Imokha Ayebae
Finance Director
FRC/2021/001/00000023145

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

Statement of Changes in Equity

	Share capital	Share premium	Retained earnings	Available- for-sale reserve	Total
	N000	N000	N000	N000	N000
At 1 January 2022	1,043,180	4,933,932	7,774,138	585	13,751,835
Bonus Issue	104,318	(104,318)	-	-	-
Profit for the year	-	-	3,439,853	(1,030)	3,438,823
Other comprehensive income for the year, net	-	-	-	-	-
Total Comprehensive Income for the year	-	-	3,439,853	(1,030)	3,438,823
Dividends (Note 32)	-	-	(1,043,180)	-	(1,043,180)
At 30 September 2022	1,147,498	4,829,614	10,170,811	(445)	16,147,478
At 1 January 2023	1,147,498	4,829,614	10,941,812	355	16,919,279
Profit for the year	-	-	3,570,966	1,490	3,572,456
Other comprehensive income for the year, net	-	-	-	-	-
Total Comprehensive Income for the year	-	-	3,570,966	1,490	3,572,456
Dividends (Note 32)	-	-	(1,262,248)	-	(1,262,248)
At 30 September 2023	1,147,498	4,829,614	13,250,530	1,845	19,229,487

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

Statement of Cash Flows

	Notes	Sep-23 N'000	Sep-22 N'000
Operating activities:			
Profit before tax		5,290,153	5,096,078
Adjustments to reconcile profit before tax tonet cash flows			
Depreciation of property, plant and equipment	14	821,474	604,807
Depreciation - Right of use assets	15	46,068	70,908
Impairment loss	8	250,000	100,000
Gain on disposal of plant, property and equipment	7	(6,758)	(48,212)
Net exchange difference	8	1,016,757	1,807,348
Depreciation of investment property	16	-	536
Grant income	7	(264,368)	(568,351)
Amortisation of Intangible assets	17	59,029	38,696
Interest income on loans and receivables	11	(1,121)	(341)
Interest income on other non Current Asset	11	-	-
Interest income on fixed deposit	11	(13,265)	(13,265)
Finance costs	10	1,379,729	1,285,998
Employee benefit expense	26	-	-
Amortisation of deferred revenue	28	-	(4,750)
Changes in working capital:			
(Increase)/ decrease in trade and other receivables	21	(5,063,418)	(2,783,910)
Decrease / (increase) in prepayments	22	(2,391,506)	(732,670)
(Increase)/ Decrease in inventories	20	(804,148)	(2,688,910)
Increase in government grant	27	207,950	76,498
increase in other financial liabilities	30	2,000,000	850,000
(Decrease)/increase in trade and other payables	29	3,642,311	1,720,413
		<u>6,168,887</u>	<u>4,810,873</u>
Income tax paid	13b	(1,396,272)	(1,379,367)
Benefits paid	26b	(1,277)	-
Net cash flow from operating activities		<u>4,771,338</u>	<u>3,431,506</u>
Cash flows from investing activities:			
Purchase of property, plant & equipment	14	(902,341)	(4,007,643)
Additions to intangible assets	17	80,247	46,429
Interest received	11	13,265	13,265
Proceeds from sale of property, plant and equipment		1,175,000	1,175,000
Investment in other Financial Asset	18c	-	520,252
Liquidation of investment in other financial asset	19	(181,761)	(172,136)
Liquidation of investment in other financial asset	19	-	173,162
Net cash utilised by investing activities		<u>184,410</u>	<u>(2,251,671)</u>
Cash flows from financing activities:			
Payments of finance lease liabilities	25	(55,582)	(71,687)
Interest paid on loans & borrowings	10	(1,379,729)	(1,285,998)
Dividend paid	31	(1,262,248)	(1,043,180)
(Payment)/refund of unclaimed dividend	32b	-	-
Proceed from loans & borrowings	24a	2,500,000	5,019,826
Loan repayment	24a	(2,452,943)	(895,551)
Net cash from financing activities		<u>(2,650,501)</u>	<u>1,723,410</u>
Net increase/(decrease) in cash and cash equivalents		2,305,247	2,903,245
Net foreign exchange difference		(1,016,757)	(1,807,348)
Cash and cash equivalents at the beginning of the year		<u>1,825,132</u>	<u>1,696,491</u>
Cash and cash equivalents at the end of the Period	23	<u>3,113,622</u>	<u>2,792,389</u>

Notes to the financial statements.

1.0 Corporate information.

The Company was incorporated as a private limited liability Company on 13 March 1995 and commenced business activities on 15 March 1995. The principal activities of the Company include manufacturing and distribution of pharmaceutical products. The Company's shares were quoted the Nigerian Stock Exchange on 5 June 2008. The issued share capital is held as to 38.86% directly by the Directors, 5.74% indirectly by the Directors and 54.94% by the Nigerian Public.

1.1 Composition of the financial statements

The Financial statements are drawn up in Naira, the functional currency of Fidson Healthcare Plc. In accordance with IFRS accounting presentation, the Financial Statements comprise:

- Statement of Profit or Loss and Other Comprehensive Income
- Statement of Financial Position
- Statement of Changes in Equity
- Statement of Cash flows
- Notes to the Financial Statements.

1.2 Financial period

These Financial Statements cover the financial period 30 September 2023 with comparative amounts for the year ended 30 September 2022.

2.0 Significant accounting policies

2.1 Basis of preparation and measurement

These financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

The financial statements have been prepared on a historical cost basis, except for certain available-for-sale financial assets which have been measured at fair value. The financial statements are presented in the Nigerian Naira and all values are rounded to the nearest thousands (₦'000), except when otherwise indicated.

2.2 Summary of significant accounting policies

The following are the significant accounting policies applied by the Company in preparing its financial statements:

Notes to the financial statements.

2.2.1 Current versus non-current classification

The Company presents assets and liabilities in statement of financial position based on current/non-current classification. An asset is current when it is:

- Expected to be realised or intended to sell or consumed in normal operating cycle.
- Held primarily for the purpose of trading.
- Expected to be realised within twelve months after the reporting period.

Or

- Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle.
- It is held primarily for the purpose of trading.
- It is due to be settled within twelve months after the reporting period.

Or

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

2.2.2 Fair value measurement

The Company measures some financial instruments and non-financial assets at fair value at each reporting date. Also, fair values of financial instruments measured at amortized cost are disclosed in Note 41a.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

Notes to the financial statements.

2.2.2 Fair value measurement (cont'd)

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the relevant observable inputs and minimizing the use of unobservable inputs. Refer to Note 42b for fair value hierarchy.

2.2.3 Revenue recognition

Revenue is recognised to depict the transfer of promised goods or services to the customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Revenue is recognised by applying a five-step approach:

- Identify the contract
- Identify the separate performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to separate performance obligations
- Recognise revenue when (or as) each performance obligation is

The Company recognises revenue from the following major sources:

- Sale of Ethical Products
- Sale of Over the Counter (OTC) products.

Revenue is measured based on the consideration to which the Company expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognises revenue when it transfers control of a product or service to a customer.

Interest income

For all financial instruments measured at amortised cost, interest income or expense is recognised using the effective interest rate (EIR), which is the rate that exactly discounts the estimated future cash payments or receipts through the expected life of the financial instrument or a shorter year, where appropriate, to the net carrying amount of the financial asset or liability. Interest income is included in finance income in the profit or loss.

Dividends

Dividends are recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend.

2.2.4 Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the period that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related asset.

Notes to the financial statements.

2.2.4 Government grants (cont'd)

When the Company receives grants of non-monetary assets, the asset and the grant are recorded at fair value amounts and released to the profit or loss over the expected useful life in a pattern of consumption of the benefit of the underlying asset by equal annual instalments. When loans or similar assistance are provided by governments or related institutions, with an interest rate below the current applicable market rate, the effect of this favourable interest is regarded as a government grant. The loan or assistance is initially recognised and measured at fair value and the government grant is measured as the difference between the initial carrying value of the loan and the proceeds received. The loan is subsequently measured as per the accounting policy in Note 2.2.12 (ii).

2.2.5 Taxes

Current income tax

The income tax assets or liabilities for the current year are measured at the amount expected to be recovered from or paid to the tax authorities. The tax rates and tax laws used to compute the amount are determined in accordance with the Companies Income Tax Act (CITA) 2007 at 30% of total profit after deducting capital allowances and loss relief. Education tax is also assessed at 2% of the assessable profits.

Current income tax relating to items recognised outside the profit or loss are recognised outside profit or loss.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates, and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

Notes to the financial statements.

2.2.5 Taxes (cont'd)

Deferred tax (cont'd)

- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that.
- the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax on items recognised in the profit or loss is also recognised in the profit or loss, while deferred tax on items recognised outside the profit or loss is also recognised outside the profit or loss.

The Company offsets deferred tax assets and deferred tax liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority on the same taxable entity.

Value Added Tax (VAT)

Revenues, expenses, and assets are recognized net of the amount of Value Added Tax (VAT), except:

- Where the VAT incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case the VAT is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable.
- Receivables and payables are stated with the amount of VAT included.

The net amount of VAT recoverable from, or payable to, the tax authority is included as part of receivables or payables in the statement of financial position.

2.2.6 Foreign currency transaction

Foreign currency transactions are converted into the functional currency, the Nigerian Naira at the rate of exchange prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency interbank rate of exchange ruling at the reporting date in accordance with the Central Bank of Nigeria guidelines. Any exchange gains or losses arising on settlement or translation of monetary items are recognised in the profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions.

Notes to the financial statements.

2.2.7 Property plant and equipment

Property, plant and equipment are stated at cost of purchase or construction, net of accumulated depreciation and/or accumulated impairment loss, if any. Such cost includes the cost of replacing component parts of the property, plant and equipment and borrowing costs for long term projects if the recognition criteria are met.

When significant parts of property, plant and equipment are required to be replaced at intervals, such parts are recognised as individual assets with specific useful lives and depreciated accordingly. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the profit or loss as incurred.

Depreciation on the categories of property, plant and equipment is calculated to write off the cost less the residual value of the asset, using the straight-line basis, over the assets' expected useful lives. Land and capital work-in-progress are not depreciated. The attributable cost of each item of capital work-in-progress is transferred to the relevant asset category immediately the asset is available for use and depreciated accordingly. The normal expected useful lives for the major categories of property, plant and equipment are:

	Years
Land	Nil
Buildings	50
Plant and machinery	4 to 25
Office equipment	4 to 10
Furniture and fittings	8
Motor vehicles	4 to 6
Capital work-in-progress (WIP)	Nil

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the profit or loss when the asset is derecognised.

The assets' residual values, useful lives and methods of depreciation are reviewed at each financial year end and adjusted prospectively, if appropriate.

Impairment reviews are performed when there are indicators that the carrying amounts may not be recoverable.

Impairment losses and reversals of impairment losses are recognised in the profit or loss.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

Notes to the financial statements.

2.2.8 Leases

The Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise:

Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable.

- Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date.
- The amount expected to be payable by the lessee under residual value guarantees.
- The exercise price of purchase options, if the lessee is reasonably certain to exercise the options; and
- Payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate the lease.

The lease liability is presented as a separate line in the statement of financial position.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

The Company remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:

The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate.

The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used).

A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.

The Company did not make any such adjustments during the periods presented.

Notes to the financial statements.

2.2.8 Leases (cont'd)

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Whenever the Company incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease, a provision is recognised and measured under IAS 37. To the extent that the costs relate to a right-of-use asset, the costs are included in the related right-of-use asset, unless those costs are incurred to produce inventories.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in the statement of financial position.

The Company applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in the 'Property, Plant and Equipment' policy.

Variable rents that do not depend on an index or rate are not included in the measurement the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs.

As a practical expedient, IFRS 16 permits a lessee not to separate non-lease components, and instead account for any lease and associated non-lease components as a single arrangement. The Company has not used this practical expedient. For contracts that contain a lease component and one or more additional lease or non-lease components, the Company allocates the consideration in the contract to each lease component based on the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company as a lessee

Finance leases transfer to the Company substantially all the risks and rewards incidental to ownership of the leased asset.

The assets are measured at the commencement of the lease at the fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised as finance costs in the profit or loss.

The capital element of assets under finance lease is capitalised along with the Company's property, plant and equipment and depreciated at the same rates for assets of that category, or over the lease term, where the lease term is shorter than the assets' useful lives.

Operating lease payments are recognised as an operating expense in the profit or loss on a straight-line basis over the lease term.

Notes to the financial statements.

2.2.8 Leases (cont'd)

Leases – as a lessor

Leases for which the Company is a lessor are classified as finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

Amounts due from lessees under finance leases are recognised as receivables at the amount of the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the Company's net investment outstanding in respect of the leases.

When a contract includes both lease and non-lease components, the Company applies IFRS 15 to allocate the consideration under the contract to each component.

2.2.9 Borrowing costs.

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period to get ready for its intended use or sale are capitalised as part of the cost of the respective assets. All other borrowing costs are expensed in the year in which they occur. Borrowing costs consist of interest and other costs that the Company incurs in connection with the borrowing of funds.

2.2.10 Investment properties

Investment properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are stated at cost less accumulated depreciation and accumulated impairment losses.

The investment properties are subject to annual depreciation charge of 2% on a straight-line basis.

If investment properties are derecognized when either they have been disposed of or when the investment property is permanently withdrawn from use and no future economic benefit is expected from its disposal. The difference between the net disposal proceeds and the carrying amount of the asset is recognized in the profit or loss in the year of derecognition.

Transfers are made to or from investment property only when there is a change in use. For a transfer from investment property to owner-occupied property, the deemed cost for subsequent accounting is the fair value at the date of change. Owner-occupied property becomes an investment property, the Company accounts for such property in accordance with the policy stated under property, plant and equipment up to the date of change in use.

Notes to the financial statements

2.2.11 Intangible assets

Product licenses are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. The Company makes upfront payments to purchase product licences. The product licenses are held on various pharmaceutical products sold by the Company and have licence years that range from 2 to 5 years. The licences may be renewed by the Company at the expiration of the licence period.

Intangible assets with finite lives are amortised over the useful economic lives. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortisation period or method, as appropriate, and treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the profit or loss in the expense category consistent with the function of the intangible asset.

Amortisation is calculated using the straight-line basis to write down the cost of intangible assets to their residual values over their estimated useful lives.

An intangible asset is derecognised on disposal or when no future economic benefit is expected from use or disposal. The gain or loss arising from the derecognition of an intangible asset is determined as the difference between the net disposal proceeds and the carrying amount of the intangible asset and recognised in the statement of profit or loss when the asset is derecognised.

Research and development costs

Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Company can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale.
- Its intention to complete and its ability and intention to use or sell the asset.
- It is probable that the asset will generate future economic benefit.
- The availability of resources to complete the asset.

Following the completion of research and development, it is transferred to another asset which is then depreciated, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete, and the asset is available for use. It is amortised over the period of expected future benefit.

Amortisation is recorded in cost of sales. During the period of development, the asset is tested for impairment annually.

Licences

The Company made upfront payments to purchase licences. Licences for the use of intellectual property are granted for periods ranging between five and ten years depending on the specific licences.

Notes to the financial statements.

2.2.11 Intangible assets (cont'd)

Trademark

The Company made upfront payments to purchase trademarks. The trademarks have been granted for a period of 5-10 years by the relevant government agency with the option of renewal at the end of this period. Licences for the use of intellectual property are granted for periods ranging between five and ten years.

A summary of the policies applied to the Company's intangible assets is, as follows:

	Licences	Trademarks	Software
Useful lives	Finite (Over 5 years)	Finite (Over 5-10years)	Finite (Over 4 years)
Amortisation method used	Amortised on a straight-line basis over the period of the licence amortisation	Amortised on a straight-line basis over the period of the trademark amortisation	Amortised on a straight-line basis over the period of the software amortisation
Internally generated acquired	Acquired or	Acquired	Acquired

2.2.12 Financial instruments

(i) Financial assets

A financial asset is any asset that is:

- cash.
- an equity instrument of another entity.
- a contractual right to receive cash or another financial asset (e.g., receivables); or
- a contractual right to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to GSK (e.g., derivatives resulting in an asset, bonds, and investments)

(ii) Financial liability

A financial liability is any liability that is:

- a contractual obligation to deliver cash or another financial asset (e.g., payable); or
- a contractual obligation to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the Company (e.g., payables, loans and derivatives resulting in a liability).

Notes to the financial statements.

2.2.12 Financial instruments (cont'd)

(iii) Amortised cost

Most of Fidson's financial assets and liabilities are measured at amortised cost, including, most trade receivables and trade payables. The amortised cost of a financial asset or financial liability is the amount at which the asset or liability is measured at initial recognition minus principal repayments to date, and minus any reduction for impairment.

If there is a difference between the initial amount and the maturity amount (arising from reasons other than impairment), amortised cost will also be plus or minus the cumulative amortisation using the effective interest method.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in profit or loss as finance costs.

(iv) Effective interest method

The effective interest method calculates amortised cost by allocating the interest payment or expense over the relevant period. This calculation only applies if a premium has been paid or a discount received. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument. When estimating cash flows, all contractual terms are considered but expected future credit losses are not taken into account unless the financial instrument is credit impaired.

(v) Expected credit loss (ECL)

The expected credit loss is the difference between the cash flows due under the contract and the cash flows expected to be received, discounted at the original effective interest rate. An expected credit loss allowance is similar to an impairment provision.

(vi) Expected credit loss allowance

An allowance for expected credit losses (ECLs) on all financial assets measured at amortised cost, e.g. most trade and other receivables, is set up through the Income Statement at initial recognition of the asset. The ECL is deducted from the carrying value of the asset on the balance sheet. Subsequent movements in the ECL (including release of the ECL if the asset is recovered in full) are reported in the Income Statement.

All ECL (impairment) allowances must be reviewed at least quarterly.

In applying the IFRS 9 impairment requirements, an entity needs to apply one of the following approaches:

- The simplified approach, which will be applied to trade receivables.
- The general approach, which will be applied to other receivables, including royalty receivables, and to loan assets and investments in debt securities.

Notes to the financial statements.

2.2.12 Financial instruments (cont'd)

(vi) Expected credit loss allowance (cont'd)

a) The simplified impairment approach.

The simplified approach applied to trade receivables requires the recognition of lifetime ECLs at all times. Fidson uses a provision matrix as a practical expedient for determining ECLs on trade receivables, including non-overdue balances. The provision matrix should incorporate forward-looking information into historical customer default rates and, where appropriate, group receivables into customer segments that have similar loss patterns, such as Distributors, Sales representatives, and Institutions.

b) The general impairment approach.

Under the general approach, prior to an asset actually being credit-impaired, entities recognise expected credit losses (ECLs) in two stages. For assets for which there has not been a significant increase in credit risk since initial recognition (i.e. 'good' exposures), entities are required to provide for ECLs that would result from default events that are possible within the next 12 months (a 12-month ECL).

For assets for which there has been a significant increase in credit risk since initial recognition, a loss allowance for ECLs expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL), is required. "

Indicators of a significant increase in credit risk include:

- An actual or expected significant change in the financial asset's external or internal credit rating.
- Existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant change in the debtor's ability to meet its debt obligations, such as an increase in interest rates or a significant increase in unemployment rates;
- An actual or expected significant change in the operating results of the debtor;
- Significant increases in credit risk on other financial instruments of the debtor;
- An actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant change in the debtor's ability to meet its debt obligations, such as a decline in the demand for the debtor's sales product because of a shift in technology;
- Expected changes in the loan documentation (i.e. changes in contract terms) including an expected breach of contract that may lead to covenant waivers or amendments, interest payment holidays, interest rate step-ups, requiring additional collateral or guarantees, or other changes to the contractual framework of the instrument;
- Significant changes in the expected performance and behaviour of the debtor, including changes in the payment status of debtor in the group (e.g., an increase in the expected number or extent of delayed contractual payments); and
- Past due information on debtors.

For current assets (expected to be recovered in less than 12 months), there will be no difference between the 12-month ECL and the lifetime ECL.

Notes to the financial statements.

2.2.12 Financial instruments (cont'd)

(vii) Impairment on available-for-sale financial investments

Available-for-sale financial assets are impaired if there is objective evidence of impairment, resulting from one or more loss events that occurred after initial recognition but before the reporting date, that have an impact on the future cash flows of the asset.

In the case of equity investments classified as available-for-sale, objective evidence would include a significant or prolonged decline in the fair value of the investment below its cost. 'Significant' is evaluated against the original cost of the investment and 'prolonged' against the year in which the fair value has been below its original cost.

When there is evidence of impairment, the cumulative loss – measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that investment previously recognized in the profit or loss – is reclassified from equity and to the profit or loss. Impairment losses on equity investments are not reversed through the profit or loss; increases in their fair value after impairment are recognized in other comprehensive income.

(viii) Derecognition of financial assets

A financial asset (or, where applicable a part of a financial asset or part of a group of similar financial assets) is derecognised when:

- The rights to receive cash flows from the asset have expired
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either
 - (a) the Company has transferred substantially all the risks and rewards of the asset, or
 - (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, and has neither transferred nor retained substantially all of the risks and rewards of the asset nor transferred control of it, the asset is recognised to the extent of the Company's continuing involvement in it.

In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Notes to the financial statements.

2.2.12 Financial instruments (cont'd)

(ix) Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the profit or loss.

(x) Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount reported in the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

2.2.13 Inventories

Inventories are valued at the lower of cost and net realisable value.

Costs incurred in bringing each product to its present location and condition is accounted for as follows:

- Raw materials are stated at purchase cost on the weighted average basis.
- Finished goods and work in progress: Cost in this case consists of direct purchase cost, conversion cost (materials, labour and overhead) and other costs incurred to bring inventory to its present condition and location. Finished goods are valued using weighted average cost
- Goods in transit are valued at the invoiced price.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

2.2.14 Impairment of non-financial assets

The Company assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

Notes to the financial statements.

2.2.14 Impairment of non-financial assets (cont'd)

Impairment losses of continuing operations are recognised in the profit or loss in expense categories consistent with the function of the impaired asset.

An assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the profit or loss.

2.2.15 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less, as shown in the statement of financial position.

For the purpose of the statement of cash flows, cash and cash equivalents comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less, as shown in the statement of financial position, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

2.2.16 Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is recognized in profit or loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

2.2.17 Pension and other post-employment benefits

Retirement benefit Schemes

The gratuity scheme is a defined benefit plan. The cost of providing the benefits under the defined benefit plan is determined using the projected unit credit method.

Actuarial gains and losses are recognized immediately in the statement of financial position with a corresponding debit or credit to retained earnings through other comprehensive income in the year in which they occur. Actuarial gains and losses are not reclassified to the profit or loss in subsequent years.

Notes to the financial statements.

2.2.17 Pension and other post-employment benefits (cont'd)

Pension

The Company operates a defined contribution plan in line with the provisions of the Pension Reform Act 2014 as amended. This plan is in proportion to the services rendered to the Company by the employees with no further obligation on the part of the Company. The Company and its employee contribute 10% and 8% respectively of employees' current salaries and designated allowances to the scheme. Staff contributions to the scheme are funded through payroll deductions while the Company's contribution is recorded as personnel expenses in the profit or loss.

Past service costs are recognized in the profit or loss on the earlier of:

- the date of the plan amendment or curtailment, and
- the date that the Company recognizes restructuring-related costs

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognizes the following changes in the net defined benefit obligation under 'cost of sales', 'administration expenses' and 'selling and distribution expenses' in statement of profit or loss (by function):

- Service costs comprising current service costs, past-service costs and gains and losses on curtailments
- Net interest expense or income

Short term benefits

Short term employee benefits are measured on an undiscounted basis and are expensed as the related service is provided. A provision is recognized for the amount expected to be paid under short term cash-bonus plans if the Company has a present and constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be measured reliably.

Termination benefits

Termination benefits are recognized as an expense when the Company is demonstrably committed without realistic possibility of withdrawal, to a formal detailed plan to terminate employment before the normal retirement date.

2.2.18 Dividends

Dividends on ordinary shares are recognised as a liability when they are approved by the Company's shareholders at the Annual General Meeting. Dividends are recognised, when they are paid. Dividends for the year that are approved after the reporting date are disclosed in the financial statements as a non-adjusting event.

Notes to the financial statements.

2.2.19 Segment reporting

For management purposes, the Company is organised into business units based on its products and has two reportable segments as follows:

- The over-the-counter segment, which represent the products that may be sold directly to the consumer without a prescription.
- Ethical products segment, which are drugs, injectables and infusion which would be sold to the consumer only on the possession of a valid prescription.
- Consumer segment, which represent household items was introduced in 2016.

No operating segments have been aggregated to form the above reportable operating segments. The Executive Management Committee monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on revenue and cost of sales. The Executive Management Committee monitors the operating results of the whole business for the purpose of making decisions about resource allocation and performance assessment.

2.2.20 Dealing in Securities by insiders

The company's directors are constantly reminded, and they are aware of the restrictions imposed on them with regards to trading in the shares of the Company during closed periods. The policy in place is obeyed by the Directors and other senior employees who by virtue of their position constantly meet price sensitive information.

Enquiries have been made and it is hereby stated that in respect of this financial statements submitted in the course of the year under review none of the Directors violated the rules relating to securities trading.

3.0 SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future years.

4.0 Application of new and revised International Financial Reporting Standards (IFRSs)

Amendments to IFRS 3 Reference to the Conceptual Framework

the Company has adopted the amendments to IFRS 3 Business Combinations for the first time in the current year. The amendments update IFRS 3 so that it refers to the 2018 Conceptual Framework instead of the 1989 Framework. They also add to IFRS 3 a requirement that, for obligations within the scope of IAS 37 Provisions, Contingent Liabilities and Contingent Assets, an acquirer applies IAS 37 to determine whether at the acquisition date a present obligation exists as a result of past events. For a levy that would be within the scope of IFRIC 21 Levies, the acquirer applies IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date.

The amendments add an exception to the recognition principle of IFRS 3 Business Combinations to avoid the issue of potential 'day 2' gains or losses arising for liabilities and contingent liabilities that would be within the scope of IAS 37 Provisions, Contingent Liabilities and Contingent Assets or IFRIC 21 Levies, if incurred separately

Notes to the financial statements.

5	Revenue		Sep-23	Sep-22
			₦'000	₦'000
	Sales of goods			
	Ethical	24,365,761	20,943,288	
	Over-The-Counter (OTC)	12,547,198	9,071,284	
	Consumer Healthcare Product	3,461,018	1,413,577	
		40,373,977	31,428,149	
	Revenue represents total value of goods invoiced to third parties locally and contract manufacturing.			
6	Cost of sales		Sep-23	Sep-22
			₦'000	₦'000
	Ethical	12,671,063	8,915,043	
	Over The Counter (OTC)	6,524,990	4,298,161	
	Consumer Healthcare Product	2,024,411	1,008,317	
	Depreciation of factory PPE (Note 14)	567,629	416,516	
	Energy	1,259,537	1,038,816	
	Personnel Cost	1,137,525	692,314	
	Other Factory Overheads	627,969	568,984	
		24,813,124	16,938,149	
7	Other operating income		Sep-23	Sep-22
			₦'000	₦'000
	Amortisation of government grant	264,368	568,351	
	Other operating income	8,332	38,374	
	Gain on disposal of property, plant and equipment	6,758	48,212	
	Rental income	-	4,750	
	Sale of scrap	59,344	25,138	
		338,802	684,824	

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

	Sep-23	Sep-22
	N'000	N'000
8 Administrative expenses		
Association and Membership	10,108	3,565
Audit fee	18,167	10,500
Conferences and Workshop	9,782	4,259
Consultancy fees	223,220	128,432
Corporate social responsibility	111,925	104,763
Depreciation and amortisation (Note 8a)	358,941	298,432
Diesel and fuel	219,696	127,960
Exchange loss	1,016,757	1,807,348
Insurance	148,459	116,955
Legal	5,186	4,391
Office supplies	9,398	14,599
Personnel costs (Note 8b)	1,910,329	1,537,911
Printing & stationery	64,465	51,947
Repairs and maintenance	84,734	91,455
Outsourced Cleaning and Security Expenses	29,787	33,362
Telephone & postage	78,802	59,086
Training	31,385	28,352
Travelling & Entertainment	434,366	267,888
Permit and Dues	82,575	42,352
Auxilliary materials & Tools	169,673	182,478
Canteen expenses	88,305	75,445
Directors Expenses	27,450	35,040
Bank administrative fee	214,050	126,044
News papers and periodicals	-	3
Impairment (Trade and other receivables)	250,000	100,000
	<u>5,607,211</u>	<u>5,264,618</u>
	Sep-23	Sep-22
	N'000	N'000
8a Depreciation and amortisation		
Depreciation of property, plant and equipment (Note 14)	821,474	604,807
Depreciation of Rights of use assets (Note 15)	46,068	70,908
Depreciation of property, plant and equipment included in cost of sales (Note 6)	<u>(567,629)</u>	<u>(416,516)</u>
	299,912	259,199
Depreciation of investment property (Note 16)	-	536
Amortisation of intangible assets (Note 17)	<u>59,029</u>	<u>38,696</u>
	<u>358,941</u>	<u>298,432</u>
8b Personnel costs		
ITF Contribution	18,575	16,414
Pension cost	63,060	45,037
Salary and wages	<u>1,828,695</u>	<u>1,476,460</u>
	<u>1,910,329</u>	<u>1,537,911</u>
9 Selling and distribution expenses		
Promotion and advertisement	821,233	1,047,422
Logistics expense	1,275,346	1,029,004
Sales expenses	<u>1,545,762</u>	<u>1,486,034</u>
	<u>3,642,342</u>	<u>3,562,461</u>

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

	Sep-23	Sep-22
	N'000	N'000
10	Finance cost	
	Interest on bank loans	1,361,450
	Interest on finance lease	18,280
		<u>1,379,729</u>
		<u>1,285,998</u>
11	Finance income	
	Interest earned on loans and receivables	19,947
		<u>19,947</u>
		<u>34,331</u>
12	Profit before tax	
	This is stated after charging:	
	Amortisation of intangibles	59,029
	Audit fee	18,167
	Depreciation of property, plant and equipment	821,474
	Depreciation of right of use assets	46,068
	Depreciation of investment property	-
	Personnel costs	1,910,329
	Exchange loss/(gain)	1,016,757
		<u>59,029</u>
		<u>38,696</u>
		<u>10,500</u>
		<u>604,807</u>
		<u>70,908</u>
		<u>536</u>
		<u>1,537,911</u>
		<u>1,807,348</u>
13	Taxation	
13a	Income tax expense	
	The major components of income tax expense for the period ended 30 September 2023	
		Sep-23
		Sep-22
		N'000
		N'000
	Current income tax:	
	Current year income tax charge	1,587,096
	Current education tax charge	132,258
		<u>1,719,354</u>
		<u>1,656,225</u>
	Total current tax	
13b	Income tax payable	Sep-23
	Current tax payable	Dec-22
		N'000
		N'000
	At 1 January	1,396,272
	Charge for the year	1,719,354
	Payments during the year	(1,396,272)
		<u>1,719,354</u>
		<u>1,396,272</u>
	At 30 September 2023	
13c	Deferred tax liability	1,389,945
	At 1 January	1,177,063
	Amounts recorded in profit or loss	-
	comprehensive income	202,727
		<u>-</u>
		<u>10,155</u>
	At 30 September 2023	<u>1,389,945</u>
		<u>1,389,945</u>

Notes to the financial statements.

14 Property, plant and equipment

COST:	LAND	BUILDING	MOTOR VEHICLES	OFFICE EQUIPMENT	PLANT & MACHINERY	FURNITURE & FITTINGS	CONSTRUCTION WIP	TOTAL
	N'000	N'000	N'000	N'000	N'000	N'000	N'000	N'000
At 1 January 2022	783,086	8,890,268	1,102,623	941,081	3,568,668	218,236	3,050,906	18,554,868
Additions	462,100	895,741	418,824	155,013	1,331,730	7,558	3,342,621	6,613,586
Disposals	(79,556)	(1,328,098)	(99,751)	(6,288)	(65,783)	-	-	(1,579,476)
Reclassification	-	-	-	-	-	-	-	-
Adjustment/Transfers	-	902,575	31,260	120,612	1,102,033	-	(2,128,980)	27,500
At 31 December 2022	1,165,630	9,360,486	1,452,956	1,210,418	5,936,648	225,794	4,264,547	23,616,478
Additions	-	-	78,655	87,307	-	10,748	725,631	902,341
Disposals	-	-	(58,298)	-	(13,625)	-	-	(71,923)
Reclassification	-	-	401,623	1,566	22,077	-	(628,038)	(202,774)
Adjustment/Transfers	-	-	-	-	-	-	-	-
At 30 September 2023	1,165,630	9,360,486	1,874,935	1,299,290	5,945,100	236,541	4,362,139	24,244,122
DEPRECIATION :								
At 1 January 2022	-	1,086,228	463,577	701,245	1,278,383	132,442	-	3,661,874
Charge for the year	-	166,644	211,971	86,332	361,761	14,652	-	841,360
Transfer out	-	-	-	-	12,430	-	-	12,430
Disposal	-	(323,516)	(89,578)	(5,463)	(46,217)	-	-	(464,775)
At 31 December 2022	-	929,356	585,970	782,114	1,606,357	147,093	-	4,050,889
Charge for the year	-	133,636	214,729	94,059	366,532	12,518	-	821,474
Reclassification	-	-	-	-	-	-	-	-
Disposal	-	-	(53,105)	-	(12,943)	-	-	(66,048)
At 30 September 2023	-	1,062,992	747,594	876,172	1,959,946	159,611	-	4,806,315
CARRYING VALUE:								
At 30 September 2023	1,165,630	8,297,494	1,127,341	423,118	3,985,154	76,930	4,362,139	19,437,807
At 31 December 2022	1,165,630	8,431,130	866,986	428,304	4,330,291	78,700	4,264,547	19,565,589

Notes to the financial statements.

- 14.1 This represents reclassification from capital work in progress to plant and machinery
- 14.2 This represents reclassification from property plant and equipment to right of use assets in line with IFRS 16.
- 14.2 Finance Lease – the carrying value of property, plant and equipment held under finance lease at 30 September 2023 was motor vehicles N16.29million, plant & machinery N311.34million (31 December 2022 motor vehicle N44.09million, plant & machinery N336.73million).
- 14.3 The company’s assets have been pledged as security for bank borrowings to the tune of the outstanding balance of total borrowings outside the Company at the reporting date (See Note 24). The company is not allowed to pledge or sell these assets as security for other borrowings or sell them to another entity.

15 **Right of Use Assets**

COST:	MOTOR VEHICLES N'000	PLANT & MACHINERY N'000	TOTAL N'000
At 1 January 2022	359,804	476,928	836,732
Additions	-	-	-
Disposals	(26,027)	-	(26,027)
Reclassification - Note 15	-	(27,500.00)	(27,500)
At 31 December 2022	333,777	449,428	783,205
Additions	-	-	-
Disposals	(107,915)	-	(107,915)
Reclassification	-	-	-
At 30 September 2023	225,862	449,428	675,290
 ACCUMULATED DEPRECIATION :			
At 1 January 2022	259,206	91,255	350,461
Charge for the year	54,596	33,855	88,451
Adjustment/Reclassification	-	(12,409)	(12,409)
Disposal	(24,115)	-	(24,115)
At 31 December 2022	289,687	112,701	402,388
Charge for the year	20,676	25,392	46,068
Disposal	(100,787)	-	(100,787)
At 30 September 2023	209,576	138,093	347,669
 CARRYING AMOUNT:			
At 31 December 2022	44,090	336,727	380,817
At 30 September 2023	16,286	311,335	327,621

The company leases motor vehicles and Plant & Machinery. The average lease term is 5 years.

Notes to the financial statements.

	Sep-23	Dec-22
	N'000	N'000
15.1 Amounts recognised in profit or loss		
Depreciation expense on right of use assets	46,068	88,451
Interest expenses on lease liabilities	18,280	38,531

There are no indications of impairment of right of use assets.

16.0 Investment Property	Sep-23	Dec-22
	N'000	N'000
Cost		
At 1 January	-	48,376
Disposal	-	-48,376
At 30 September 2023	-	-
Accumulated depreciation		
At 1 January	-	16,553
Charge for the year		536
Disposal		-17089
At 30 September 2023	-	-
Carrying amount	-	-

The only investment property held by Fidson Healthcare Plc is the premises used by Ecomed. The rental commenced in March 2010. The property was disposed in 2022.

	Sep-23	Dec-22
	N'000	N'000
Rental income derived from investment property	-	4,750

The company has no restrictions on the realisability of its investment property and no contractual obligations to purchase, construct or develop investment property or for repairs, maintenance and enhancements.

Notes to the financial statements.

17.0 **Intangible assets**

Product licences	Sep-23 N'000	Dec-22 N'000
Cost:		
At 1 January	372,629	315,279
Additions	<u>80,247</u>	<u>57,350</u>
At 30 September 2023	<u>452,876</u>	<u>372,629</u>
Amortisation		
At 1 January	349,084	293,557
Charge for the year	<u>59,029</u>	<u>55,528</u>
At 30 September 2023	<u>408,113</u>	<u>349,084</u>
Carrying amount	<u>44,763</u>	<u>23,545</u>

The product licenses are intangible assets with finite life and are amortized in line with the provisions of IAS 38. The intangible assets are tested for impairment when there are indicators of impairment in line with the provisions of IAS 36, by comparing the recoverable amount with the carrying amount at the end of the reporting period. There were no indicators of impairment during the year.

18 **Financial assets**

The company's financial instruments are summarised by categories as follows:

	Sep-23 N'000	Dec-21 N'000
Financial Instrument(18a)	6,290	4,800
Loans and receivables (18b)	<u>15,813</u>	<u>14,692</u>
Total financial instruments	<u>22,103</u>	<u>19,492</u>

18a **Financial Instrument**

Quoted equity at fair value (Zenith Bank Plc)		
At 1 January	4,800	5,030
Gain/(Loss)	<u>1,490</u>	<u>(230)</u>
Total	<u>6,290</u>	<u>4,800</u>

Notes to the financial statements.

	Sep-23	Dec-22
	N'000	N'000
18b Loans and receivables		
Investment with Cardinal Stone Partners		
At 1 January	12,876	12,304
Additions	-	-
Drawdown	-	-
Interest accrued	1,121	572
Sinking Fund	1,816	1,816
	<u>15,813</u>	<u>14,692</u>
At 30 September	<u><u>15,813</u></u>	<u><u>14,692</u></u>
The amount represent investment towards gratuity payment		
	Sep-23	Dec-22
	N'000	N'000
19a Other non –current financial asset		
Meristem Trustees		
At 1 January	174,542	-
Transfer Fro ALM Trustees	-	171,423
Accrued interest	7,219	3,119
	<u>181,761</u>	<u>174,542</u>
At 30 September	<u><u>181,761</u></u>	<u><u>174,542</u></u>
	Sep-23	Dec-22
	N'000	N'000
20 Inventories		
Finished goods	4,259,832	5,929,253
Goods-in-transit	3,419,589	4,198,120
Raw and Packaging materials	4,696,553	4,047,366
Work- in- progress	820,350	93,019
Engineering spare parts	281,766	330,774
Promotional and Other Consumable Materials	133,050	140,046
	<u>13,611,140</u>	<u>14,738,578</u>
Total inventory writedown	<u>(151,792)</u>	<u>(131,792)</u>
	<u><u>13,459,348</u></u>	<u><u>14,606,786</u></u>
20a Inventories Writedown	Sep-23	Dec-22
	N'000	N'000
at I January	(131,792)	(75,792)
Addition	(20,000)	-
Write off	-	(56,000)
	<u>(151,792)</u>	<u>(131,792)</u>

The company did not pledge any inventory as collateral for loans.

Notes to the financial statements.

	Sep-23 ₦'000	Dec-22 ₦'000
21 Trade and other receivables		
Trade receivables (Note 21a)	9,188,908	3,974,730
Impairment loss (Note 21b)	<u>(386,218)</u>	<u>(136,219)</u>
	8,802,690	3,838,511
Other Receivables (Note 21c)	<u>510,124</u>	<u>410,885</u>
	<u><u>9,312,814</u></u>	<u><u>4,249,396</u></u>

21a Trade receivables meet the definition of financial asset and the carrying amount of the trade receivables approximates their fair value. Trade receivables are expected to be fully collected within 1 year.

21b As at 30 September 2023, trade receivables of an initial value of ₦386.22million (2022: ₦136.22million) were impaired and provided for. See below for the movements in the provision for impairment of trade receivables.

	Individually impaired '₦000
At 1 January 2022	136,218
Addition	250,000
Write off of trade receivables	<u>-</u>
At 30 September 2023	<u><u>386,218</u></u>
At 1 January 2022	182,069
Addition	(45,851)
Write off of trade receivables	<u>-</u>
At 31 Dec 2022	<u><u>136,218</u></u>

Notes to the financial statements.

	Sep-23	Dec-22
	₦'000	₦'000
21c. Other receivables		
Withholding tax receivables (WHT)	163,068	158,040
Staff advances and other debtors	<u>347,057</u>	<u>252,845</u>
	<u><u>510,124</u></u>	<u><u>410,885</u></u>

Other receivables relate to withholding tax, value added tax receivables and staff advances. These are not interest bearing and repayment is within 1 year.

	Sep-23	Dec-22
	₦'000	₦'000
22 Prepayments		
Advance to suppliers	3,907,162	1,554,422
Other prepayments	<u>330,335</u>	<u>291,568</u>
	<u><u>4,237,497</u></u>	<u><u>1,845,991</u></u>

This represents advances made to suppliers for the purchase of factory raw and packaging materials. Other prepayments include prepaid advert, prepaid insurance, prepaid rent and equipment.

	Sep-23	Dec-22
	₦'000	₦'000
23 Cash and cash equivalents		
Bank balances	3,805,636	2,097,321
Cash at hand	50,470	15,790
Short-term deposits (including demand and time deposits)	<u>221</u>	<u>2,025</u>
Total cash and cash equivalents	<u><u>3,856,327</u></u>	<u><u>2,115,137</u></u>

Short-term deposits are made for varying years of between one day and three months, depending on the immediate cash requirements of the Company and weighted average interest rate is at 9.20%.

For the purpose of cash flows, cash and cash equivalents consist of:

	Sep-23	Dec-22
	₦'000	₦'000
Bank overdraft (Note 23.1)	(742,705)	(290,004)
Cash and cash equivalents	<u>3,856,327</u>	<u>2,115,137</u>
	<u><u>3,113,622</u></u>	<u><u>1,825,133</u></u>

23.1 Bank overdraft represents the outstanding commitment on short-term borrowings for working capital management. The bank overdrafts are secured against mortgage debenture held by a trustee. The lenders are Access Bank, FCMB and FSDH. The interest on the overdraft ranges from 15– 18%.

Cash at banks in some classified account (e.g Call accounts, DSRA account and others) earn interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and three months, depending on the immediate cash requirements of the Company, and earn interest at the respective short-term deposit rates.

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

Notes to the financial statements.

	Sep-23 ₦'000	Dec-22 ₦'000
24 Interest Bearing Loans and borrowings		
(Non-current portion)		
Bank of Industry ('BOI')(24f)	1,000	1,000
First City Monument Bank - RSSF (24c)	-	-
Bank of Industry Term Loan N5billion	3,299,088	3,299,088
Bank of Industry ('BOI') 4 (Note 24b)	494,439	494,439
First City Monument Bank (Note 25h)	-	-
CBN DCRR/FCMB-working Capital(Note 24d)	-	-
NEXIM/Fidelity-Capex(Note 24e)	624,173	624,173
CBN DCRR/FCMB-Capex(Note 24d)	1,327,739	1,327,739
NEXIM/Fidelity-working capital (24e)	-	-
Bank of Industry N2.5Billion	2,001,590	-
	<u>7,748,029</u>	<u>5,746,439</u>
(Current portion)		
Bank of Industry ('BOI') (24f)	-	-
Fidelity Bank (Note 25e)	-	-
First City Monument Bank - RSSF (24c)	-	82,033
Bank of Industry Term Loan 3billion	521,035	1,041,450
Bank of Industry ('BOI') 4 (Note 24b)	45,135	165,230
First City Monument Bank (Note 24h)	-	-
CBN DCRR/FCMB-working Capital(Note 24d)	-	466,051
CBN/DCRR/FCMB - CAPEX	132,406	298,390
NEXIM/FIDELITY	134,756	400,000
NEXIM/Fidelity-working capital (24e)	-	1,498,078
Bank of Industry N2.5Billion	24,671.00	-
Short term borrowings (Note 24g)	2,978,871	1,847,180
	<u>3,836,873</u>	<u>5,798,413</u>
Total	<u>11,584,903</u>	<u>11,544,852</u>
24a Reconciliation of interest bearing loans		
At 1 January	11,544,853	8,410,848
Interest expense	1,361,450	1,772,656
Additions	2,500,000	5,019,826
Principal repayment	(2,459,951)	(1,885,821)
Interest paid	(1,361,450)	(1,772,656)
	<u>11,584,903</u>	<u>11,544,853</u>
AT 30 September	<u>11,584,903</u>	<u>11,544,853</u>
24b	The BOI loan of N1bn was granted in 2019 at 10% for 84 months for capital expenditure. The fair value of the loan was obtained using estimated market rate of 18%. The difference between the loan rate and market rate accounted for a grant element of N161m. This was recognised as government grant and will be recognised in profit or loss over the duration of the loan. The moratorium on principal repayment of BOI loan has been extended by one year, this is to cushion the effect of the covid pandemic. 2% reduction in interest rate was also granted until August 31,2022 while 9% interest rate commenced September 1,2022	
24c	RSSF loan is a N1.5billion Central Bank of Nigeria (CBN) Real Sector Support Facility granted to Fidson Healthcare Plc at 9% for 60 months. A fair value of the loan was obtained using estimated market rate of 17%. The difference between the loan rate and market rate accounted for a grant element of N213m which has been recognised as government grant and will be recognised over the duration of the loan. The loan was granted in 2018 for the acquisition of Gas Generators and other pharmaceutical machinery for the factory. The interest on RSSF loan was reduced to 5% to cushion the effect of the pandemic until August 31,2022 while 9% interest rate commenced September 1,2022	
24d	FCMB loan is a N2.5billion Central Bank of Nigeria (CBN) Real Sector Support Facility-Differentiated Cash Reserve Requirement granted to Fidson Healthcare PLC for 84 months. The principal and interest shall be in twenty equal instalment and the interest shall be 9% per annum. However the CBN concessionary rate of 5% will apply till August 31,2022 while 9% interest rate commenced September 1,2022	

Notes to the financial statements.

24e Nexim Loan is a N3billion Nigerian Export-Import bank loan under the direct leading scheme to Fidson healthcare PLC at the rate of 9% per annum, the loan was disbursed in two equal instalment, N1.5billion for equipment finance and the other for working capital utilization.

24f The new BOI facilities are 6-year period term loans amounting to N5billion of which the sum of N2billion was disbursed during the year 2021 while the balance was disbursed in the current year. The initial interest rate on the facility is 5% which will elapse in August 31,2022 and 9% subsequently to the end of the facility

24g Short- term borrowings above are current and are expected to be settled within 12 months of the reporting date. The loans are import finance facilities from First City Monument Bank and FSDH Marchant Bank. The Security for the borrowings is a legal mortgage over the company's All Asset Debenture. Also included in the short term borrowing is N1.15bn Letters of Credit established by Wema Bank, yet to be debited from our account. The transaction is cash-backed and the corresponding cash balance is included in cash and bank balances as at 30 September 2022. The carrying value of short term borrowings approximates their fair value-due to the short-term nature and the fact that there were no material movement in market rates since the inception the loans.

25 Obligation under finance lease

The company has entered into commercial leases on certain motor vehicles. These leases have an average life of between three and five years with no renewal option included in the contracts. There are no restrictions placed upon the Company by entering into these leases.

25a	Maturity analysis	Sep-23	Dec-22
		₦'000	₦'000
	Year 1	63,590	63,590
		<hr/> 63,590	<hr/> 63,590
	Less Unearned Interest	(63,590)	(8,008)
		<hr/> <hr/> -	<hr/> <hr/> 55,582
	Analysed as		
	Current	-	55,581
	Non Current	-	-
	At 30 September 2023	<hr/> <hr/> -	<hr/> <hr/> 55,581

25a	Reconciliation of obligation under finance lease	Sep-23	Dec-21
		₦'000	₦'000
	At 1 January	55,582	260,441
	Additions	-	-
	Repayment	(55,582)	(204,859)
		<hr/> <hr/> -	<hr/> <hr/> 55,582

26 Retirement benefit obligation

Net benefit expense (recognised in administrative expenses)

		Sep-23	Dec-22
		₦'000	₦'000
	Interest cost on benefit obligation	<hr/> -	<hr/> 33,851
	Net benefit expense	-	33,851
	Defined benefit liability	<hr/> <hr/> 262,325	<hr/> <hr/> 263,602

FIDSON HEALTHCARE PLC
Unaudited report and financial statements
For the period ended 30 September 2023

Notes to the financial statements.

26b Changes in the present value of the defined benefit obligation are as follows:

	Sep-23	Dec-22
	N'000	N'000
Defined benefit liability at 1 January	263,602	268,185
Interest cost	-	33,851
Benefits paid	(1,277)	(4,583)
Re-measurement gain on obligation (experience adjustment)		(33,851)
	262,325	263,602
	Sep-23	Dec-22
	N'000	N'000
27 Government grant		
At 1 January	997,887	1,017,415
Additions	948,527	687,642
Released to profit or loss	(740,576)	(707,170)
	1,205,837	997,887
At 30 September 2023		
Current	106,411	346,595
Non-current	1,099,427	651,291
	1,205,837	997,887

This represents the grant elements of the Central Bank of Nigeria intervention loans, after the loans were re-measured using the effective interest rate. The government grants have been recognised in the statement of financial position and are being amortised through the profit or loss on a systematic basis over the tenure of the loans.

	Sep-23	Dec-22
	N'000	N'000
29 Trade and other payables		
Trade payables	6,339,404	3,849,769
Accruals	2,280,167	2,427,799
Other payables (Note 29a)	1,017,774	738,156
	9,637,346	7,015,724
29a. Other payables		
Other creditors	257,104	469,853
Withholding tax (WHT)	432,972	153,998
Nigeria Social Insurance Trust Fund (NSITF)	-	6,153
Payable to the Directors	245,909	55,833
Pay as you earn (PAYE)	45,322	37,837
Staff Cooperative	5,545	309
NHF	986	1,005
VAT Payable	1,190	511
Staff Pension Fund	10,746	12,657
Non Executive Directors	18,000	-
	1,017,774	738,156

Notes to the financial statements.

Other creditors are non-interest bearing and have an average term of six months. Trade payables, and other payables meet the definition of financial liability and their carrying amounts approximate fair value because the terms and conditions of payment is within 1 year for trade and other payables.

	Sep-23 N'000	Dec-22 N'000
30 Other Current Financial Liabilities		
Commercial papers	5,000,000	3,000,000
	5,000,000	3,000,000

Other current financial liability is the 269days N5.0billion commercial paper raised at 13% to augment the working capital.

	Sep-23 N'000	Dec-22 N'000
31 Dividends		
Dividends paid and proposed	1,262,248	1,043,180
Paid during the year	(1,262,248)	(1,043,180)
	-	-
Balance unpaid	-	-
Dividends on ordinary shares:		
Dividend proposed for 2022: N0.55k per share (2021 : N0.50k per share)	1,262,248	1,043,180

	Sep-23 N'000	Dec-22 N'000
31a Unclaimed dividend		
Unclaimed dividend	108,140	108,140

Unclaimed dividend relates to dividend paid in the prior year which was returned by the registrar as they remained unclaimed by the beneficiaries.

	Sep-23 N'000	Dec-22 N'000
31b Reconciliation of unclaimed dividend		
At 1 January	108,140	88,215
Additions	-	1,043,180
Payment	-	(1,043,180)
(Payment)/refund of unclaimed dividend	-	19,925
	108,140	108,140
At 30 September 2023	108,140	108,140

Notes to the financial statements.

32 Share capital and reserves

	Sep-23	Dec-22
	N'000	N'000
Issued and fully paid:		
2,086,360,250 ordinary shares of 50k each	1,147,498	1,043,180
208,636,025 ordinary shares of 50k each	-	104,318
	1,147,498	1,147,498

A total of 105,003,725 ordinary shares of 50 kobo each of the company have been earmarked for the company's Employee share scheme (Long Term Incentive Plan) as approved by the shareholders at the 22nd Annual General Meeting in 2022. The shares will only become part of the company's issued share capital when they are duly registered with the Securities and Exchange Commission.

33 Share premium

	Sep-23	Dec-22
	N'000	N'000
At 1 January	4,829,614	4,933,932
Bonus Share of 50k each for 10 ordinary share	-	(104,318)
At 30 September 2023	4,829,614	4,829,614

Section 120.2 of Companies and Allied Matters Act requires that where a Company issues shares at premium (i.e. above the par value), the value of the premium should be transferred to share premium.

Share premium arose as a result of premium paid on increase in share capital of 50k from 200,000,000 to 1,500,000,000 and 1,500,000,000 to 2,086,360,250 ordinary shares in November 2007 and April 2019 respectively.

A bonus issue of 208,636,025 ordinary share of 50kobo each by way of one new ordinary share of 50 kobo for every 10 ordinary share held as at the close of business on July 8, 2022 was approved by SEC in August 2022.

34 Financial Asset reserve

The reserve records fair value changes in available for sale financial asset.

	Sep-23	Dec-22
	N'000	N'000
At 1 January	355	585
Other Comprehensive income for the year, net	1,490	(230)
At 30 September 2023	1,845	355

Gain or loss on equity available for sale financial asset is not taxable. Hence, no deferred tax was recognised for fair value gain or loss. This is to aid any user of the financial statement not familiar with Nigerian tax laws.